Losing Altitude? How should astronaut launch into atmosphere

European Journal of Heart Failure

Volumn 15, Issue 11, 2013, Pages 1205-1207

  Krum, Henry ^a   Massie, Barrie ^b   Abraham, William T ^c   Dickstein, Kenneth ^d,e   Kober, Lars ^f   McMurray, John J V ^g  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF BERGEN   (Norway)

^f International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALISKIREN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; MINERALOCORTICOID ANTAGONIST; PLACEBO; RENIN; RENIN INHIBITOR;

ACUTE HEART FAILURE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK REDUCTION; SUDDEN CARDIAC DEATH; SYSTOLIC HEART FAILURE;

AMIDES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; FUMARATES; HEART FAILURE; HUMANS; RENIN; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84890061005     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hft133     Document Type: Editorial

References (13)

1. Angeli F, Reboldi G, Mazzotta G, Poltronieri C, Garofoli M, Ramundo E, Biadetti A, Verdecchia P. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions. Curr Drug Saf 2012;7:76-85
2. Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A. Angiotensin 2 reactivation and aldosterone escapephenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother 2007; 8:529-535
3. Danser AH. (Pro)renin receptors: are they biologically relevant? Curr Opin Nephrol Hypertens 2009;18:74-78
4. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-2213
5. Gheorghiade M, BöhmM, Greene SJ, FonarowGC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP; ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissionsamong patientshospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013;309:1125-1135
6. Krum H, Massie B, Abraham WT, Dickstein K, Kober L, McMurray JJ, Desai A, Gimpelewicz C, Kandra A, Reimund B, Rattunde H, Armbrecht J; ATMOSPHERE Investigators. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to MinimizeOutcomeS in Patients with HEart failure (ATMOSPHERE) study. Eur J Heart Fail 2011;13:107-114
7. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007;357:28-38
8. Drazen JM, Wood AJJ. Don't mess with the DSMB. N Engl J Med 2010;363: 477-478
9. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B, Heidenreich PA, Knabel T, Konstam MA, Steimle A, Warner Stevenson L. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003;41:1529-1538
10. Krum H, Carson P, Farsang C, Maggioni AP, Glazer RD, Aknay N, Chiang YT, Cohn JN. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 2004;6: 937-945
11. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906
12. Solomon SD, Shin SH, Shah A, Skali H, Desai A, Kober L, Maggioni AP, Rouleau JL, Kelly RY, Hester A, McMurray JJ, Pfeffer MA; Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) Investigators. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J 2011;32:1227-1234
13. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24